Cellular Senescence and Brain Aging: The Therapeutic Promise of Senolytics in Neurodegenerative Diseases – A Scoping Review

A BSTRACT Cellular senescence is increasingly recognized as a key driver of brain aging and neurodegenerative diseases. Senolytic drugs that selectively eliminate senescent cells have emerged as a promising therapeutic strategy. This scoping review maps the current evidence on senolytic interventions targeting cellular senescence in brain aging and neurodegenerative diseases. We conducted a systematic search across Google Scholar, PubMed, and ClinicalTrials.gov (2015–2025). Studies were screened and data extracted using standardized forms. Results were synthesized thematically following Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews guidelines. Of 48 records screened, 46 studies were included (3 clinical trials, 24 preclinical studies, 19 reviews). Two clinical trials (SToMP-AD and STAMINA) demonstrated safety and target engagement of dasatinib + quercetin (D + Q) in Alzheimer’s disease. Preclinical evidence strongly supports senolytic efficacy in improving cognition and reducing neuroinflammation. Senolytic therapy shows promise for neurodegenerative diseases, but larger clinical trials are needed. Critical gaps include optimal dosing, biomarker development, and long-term safety data.